Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients
- 1 September 2024
- journal article
- research article
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (17) , 1996-2007
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting StentsJACC: Asia, 2021
- Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics TrialAmerican Journal of Cardiovascular Drugs, 2021
- Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent ImplantationJAMA Cardiology, 2021
- Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary InterventionJAMA, 2020
- Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCIJAMA, 2019
- Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary InterventionJAMA, 2019
- Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMIJACC, 2017
- Validation of BARC Bleeding Criteria in Patients With Acute Coronary SyndromesJACC, 2016
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studiesInternational Journal of Surgery, 2014
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCIJAMA, 2010